Feasibility Study on the Use of Redormin®500 on Day-time Cognition
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, parallel groups, placebo-controlled, baseline/run-in period of 21
days followed by trial period of 21 days, digital phenotyping (sleep, cognitive/psychological
parameters and HRV).
The aim of this study is to determine the feasibility of investigating the effects of
Redormin® 500 on day-time cognition and to assess psychological parameters (subjective
cognitive performance, tiredness, mood, stress level, quality of life, motivation), in people
with occasional sleep problems.
Sleep tracking data will be collected using consumer devices of the Charge series by Fitbit.